2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

2:30PM-4:00PM: Abstract Number: 888

Phase 3 Trial Results with Blisibimod, a Selective Inhibitor of B-Cell Activating Factor, in Subjects with Moderate-to-Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 854

Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers

Muscle Biology, Myositis and Myopathies

2:30PM-4:00PM: Abstract Number: 855

Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo

Pain – Basic and Clinical Aspects Oral

2:30PM-4:00PM: Abstract Number: 838

Rates of New-Onset Pulmonary Disease Among Patients with Systemic Lupus Erythematosus in Sweden

Epidemiology and Public Health I: Lung, Bone, and Infection Outcomes

2:30PM-4:00PM: Abstract Number: 857

Relation of Pain Sensitization to Low Physical Function: The Multicenter Osteoarthritis Study

Pain – Basic and Clinical Aspects Oral

2:30PM-4:00PM: Abstract Number: 837

Rheumatoid Arthritis and Risk for Chronic Obstructive Pulmonary Disease or Asthma Among Women during 38 Years of Prospective Follow-up

Epidemiology and Public Health I: Lung, Bone, and Infection Outcomes

2:30PM-4:00PM: Abstract Number: 842

Risk of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologic Vs. Non-Biologic Dmards

Epidemiology and Public Health I: Lung, Bone, and Infection Outcomes

2:30PM-4:00PM: Abstract Number: 852

RNAseq Detection of Gene Dysregulation in PBMCs from Juvenile Dermatomyositis, Positive for p155/140 Myositis Specific Antibody

Muscle Biology, Myositis and Myopathies

2:30PM-4:00PM: Abstract Number: 875

Serum Autoantibody Profiling of Primary Sjoegren’s Syndrome Patients Reveals Novel Biomarkers Associated with the Disease, Disease Activity, and Clinical Response to VAY736

Sjögren's Syndrome I: Clinical Assessment and Trial Outcomes

2:30PM-4:00PM: Abstract Number: 832

Single Cell Analysis Reveals Heterogeneity of Type I IFN Gene Expression in Developing Autoreactive B Cells

B Cell Biology and Targets in Autoimmune Disease

2:30PM-4:00PM: Abstract Number: 846

Social Support in Couples-Focused Physical Activity Interventions for People with Hip or Knee Osteoarthritis: What Kinds of Partner Support Are Associated with Increases in Physical Activity and Reductions in Sedentary Behavior?

ARHP Psychosocial Impact on Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 844

Social Support, Stress and Health Outcomes in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort

ARHP Psychosocial Impact on Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 890

Synergetic B-Cell Immunomodulation with Rituximab and Belimumab Combination Treatment in Severe, Refractory SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 895

Temporal Trends in Incidence and Outcomes of End-Stage Renal Disease Due to Granulomatosis with Polyangiitis in the US from 1995-2014

Vasculitis I: Clinical Trials and Outcomes

2:30PM-4:00PM: Abstract Number: 847

The Mediational Role of Helplessness in Psychological Outcomes in Systemic Lupus Erythematosus

ARHP Psychosocial Impact on Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].